DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of TZIELD™ (teplizumab-mzwv) and Updates Long-Term Cash Receipts Outlook
– Transaction adds a ground-breaking type 1 diabetes therapy to DRI’s expanding portfolio – – Excluding any new transactions, DRI now expects 2030 cash receipts to be at least as high as 2022 cash receipts – – Extends DRI’s overall portfolio duration to over 10 years – TORONTO, March 8, 2023 /CNW/ – DRI Healthcare […]
DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2022 Results
– 2022 deployment of US$281 million continues to validate growth strategy – – Continued strong performance of existing assets and financial results – TORONTO, March 1, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. […]
DRI Healthcare Trust to Host Fourth Quarter and Full Year 2022 Earnings Call and Webcast on March 2, 2023
TORONTO, Feb. 16, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it will hold a conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, March 2, 2023, at 8:00 a.m. ET. The Trust will report its financial results on Wednesday, […]
DRI Healthcare Trust Announces US$95 million Private Placement of Preferred Securities and Increased Deployment Target
– Provides additional capital to fund biopharmaceutical research, driving value for DRI’s unitholders and partners – TORONTO, Feb. 8, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it has completed a private placement of US$95 million of preferred securities (the “Private Placement”) to an investor group that […]
DRI Healthcare Trust Declares Unit Distribution and Provides Update on Normal Course Issuer Bid
TORONTO, Dec. 21, 2022 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that, in accordance with the requirement for the Trust to distribute all of its taxable income for the year, the Board of Trustees has declared a special unit distribution of US$0.1655 per unit, which will be […]
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency
– Transaction adds another innovative rare disease therapy to DRI’s expanding portfolio – – Deal structure offers risk sharing with milestone payments for positive performance – –…
DRI Healthcare Trust Reports Third Quarter 2022 Results
– Transactions for Empaveli, Zejula and Omidria royalties mark significant progress – – Cash receipts expected to be flat to slightly increasing through 2025 even with no further deployment – -…
DRI Healthcare Trust Announces Appointment of Poonam Puri to Board of Trustees
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced Poonam Puri has been appointed as an independent member of the Trust’s board of trustees effective…
DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 8, 2022
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its third quarter 2022 financial results on Tuesday, November 8,…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Omidria® for Intracameral Use During Cataract Surgery or Intraocular Lens Replacement
– Transaction adds a well-established ophthalmology product that generates substantial near-term cash flows, with long-term structural growth anticipated – – Third transaction of 2022 with US$184.5 million deployed YTD – – DRI to hold conference call to provide business update at 10:00 am ET this morning – TORONTO, Oct. 3, 2022 /CNW/ – DRI Healthcare […]